Deyin Xing, MD, PhD
Assistant Professor of Pathology

The Johns Hopkins University
Baltimore, Maryland, USA
Phone: 443‐287‐7980


1992-1999 B.M., M.Med. (equivalent to M.D. in US), Nankai University School of Medicine,Tianjin, China
1999-2002 Ph.D., Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2002-2003 Research Assistant, Department of Environmental Medicine, New York University, School of Medicine, Tuxedo, NY
2003-2007 Research Fellow, Department of Pathology, Molecular Pathology Unit, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA
2007-2011 Postdoctoral Associate, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
2011-2014 Resident, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL
2014-2016 Clinical Fellow/Faculty Assistant, Department of Pathology, The Johns Hopkins University, Baltimore, MD
2016-Present Assistant professor, Department of Pathology, The Johns Hopkins University, Baltimore, MD


Deyin Xing, M.D., Ph.D., is currently an Assistant Professor in the Division of Gynecologic Pathology at the Johns Hopkins Hospital. He earned his medical degree in 1999 from Nankai University in Tianjin, China. Following medical school, he spent three years completing a doctoral degree in oncology, under the supervision of Dr. Dongxin Lin, at Peking Union Medical College in Beijing. In 2003, he joined the laboratory of Dr. Sandra Orsulic as a research fellow in the department of pathology at the Massachusetts General Hospital/Harvard Medical School where his research focused on the development of genetically engineered mouse models of ovarian cancer and of leiomyosarcoma. In 2007, Dr. Xing joined the laboratory of Nobel Prize Laureate Dr. Phillip Sharp at the David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology where his translational research involved the delivery of siRNAs to silence genes in genetically defined murine ovarian tumor models.

Dr. Xing resumed his clinical career as an anatomic pathology resident in 2011 in the department of pathology at the University of Alabama at Birmingham. In 2014, he came to Hopkins for a gynecologic pathology fellowship training mentored by Dr. Robert Kurman, Dr. Biggy Ronnett and Dr. Russell Vang. Dr. Xing’s clinical and translational research centers on novel diagnostic and prognostic markers of gynecologic neoplasms and molecular alterations of these tumor. He is currently an editorial board member for Diagnostic Pathology and a review editor for Frontiers in Cell and Developmental Biology (Molecular Medicine).

Research Interest

  • Gynecologic pathology
  • Gynecologic oncology
  • Epigenetics

Scientific Activities

2016‐present Assistant Professor of Pathology, The Johns Hopkins University
2016‐present Active Staff, The Johns Hopkins Hospital
Clinical activities
  • Clinical Focus - Gynecologic pathology
  • Medical, other state/government licensure  - Maryland medical license
  • Boards, other specialty certification - American Board of Pathology – Anatomic Pathology (2014)
  • Membership in or examiner for specialty board - The United States and Canadian Academy of Pathology (USCAP)
  • The International Society of Gynecological Pathologist (ISGyP)
  • Chinese American Pathologists Association (CAPA)
Honors and Awards
  • 2002 - Chinese Medical Science and Technology Award
  • 2004 - Beijing Science and Technology Advancement Award
  • 2005 - Massachusetts General Hospital Fund for Medical Discovery (FMD) Award
  • 2005 - U.S. Department of Defense (DOD) Ovarian Cancer Research Program (OCRP) Institutional Training Award
  • 2006 - American Association for Cancer Research (AACR) Scholar‐in‐Training Award
  • 2006 - The Ann Schreiber Mentored Investigator Award, Ovarian Cancer Research Fund Alliance (OCRFA)
  • 2006 - The Marsha Rivkin Center Scientific Scholar Award (declined due to funding overlap)
  • 2012 - UAB Department of Pathology Adams Resident Research Fund Award
  • 2014 - UAB Department of Pathology Adams Resident Research Fund Award
  • 2016 - Cervical Cancer SPORE Career Development Award


Original Research
  1. Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM. Next‐generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. Am J Surg Pathol. 2018 Mar 2. [Epub ahead of print].
  2. Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB. Aberrant Pax‐8 expression in well differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. Hum Pathol. 2018 Feb;72:160‐166.
  3. Jahanseir K, Xing D, Greipp PT, Sukov WR, Keeney GL, Howitt BE, Schoolmeester JK. PDGFB Rearrangements in Dermatofibrotuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol. 2017 Nov 14. [Epub ahead of print].
  4. Xing D, Suryo Rahmanto Y, Zeppernick F, Hannibal CG, Kjaer SK, Vang R, Shih IM, Wang TL. Mutation of NRAS is a rare genetic event in ovarian low‐grade serous carcinoma. Hum Pathol. 2017 Oct;68:87‐91
  5. Sayeed S, Xing D, Jenkins SM, Weisman PS, Buehler D, Warmke L, Uram‐Tuculescu C, Bakkum‐ Gamez JN, Howitt BE, Cortese C, Park KJ, Schoolmeester JK. Criteria for Risk Stratification of Vulvar and Vaginal Smooth Muscle Tumors: An Evaluation of 71 Cases Comparing Proposed Classification Systems. Am J Surg Pathol. 2018 Jan;42(1):84‐94.
  6. Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS. Early and consistent overexpression of ADRM1 in ovarian high‐grade serous carcinoma. J Ovarian Res. 2017 Aug 7;10(1):53.
  7. Schoolmeester JK, Xing D, Keeney GL, Sukov WR. Genital Rhabdomyoma of the Lower Female Genital Tract: A Study of 12 Cases with Molecular Cytogenetic Findings. Int J Gynecol Pathol. 2017 Jul 11. [Epub ahead of print].
  8. Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings HM. Frequent NFIB‐associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. Int J Gynecol Pathol. 2017 May;36(3):289‐293.
  9. Xing D, Schoolmeester JK, Ren Z, Isacson C, Ronnett BM. Lower female genital tract tumors with adenoid cystic differentiation: p16 expression and high‐risk HPV detection. Am J Surg Pathol. 2016 Apr;40(4):529‐36.
  10. Xing D, Qasem SA, Owusu K, Zhang K, Siegal GP, Wei S. Changing Prognostic Factors in Osteosarcoma: Analysis of 381 Cases from Two Institutions. Human Pathology. 2014 Aug; 45(8): 1688‐96.
  11. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Decitabine enhances lymphocyte migration and function and synergizes with CTLA‐4 blockade in a murine ovarian cancer model. Cancer Immunol Res. 2015 Sep; 3(9):1030‐41.
  12. Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(‐/‐) murine model of ovarian cancer. Biochem Biophys Res Commun. 2015 Aug 7; 463(4):551‐6.
  13. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC. CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. Cancer Res. 2011 Aug 15; 71(16): 5522‐34.
  14. Goldberg MS*, Xing D*, Ren Y, Orsulic S, Bhatia S, Sharp PA. Nanoparticle‐mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1‐deficient ovarian cancer cells. Proc Natl Acad Sci USA. 2011, Jan 11; 108(2): 745‐50. *Co‐First author.
  15. Ibrahim N, He L, Leong C, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. BRCA1‐ associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010 Sept 15; 70(18): 7155‐65.
  16. Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res. 2009 Nov 1; 69(21): 8231‐5.
  17. Agrawal A, Min DH, Singh N, Zhu H, Birjiniuk A, von Maltzahn G, Harris TJ, Xing D, Woolfenden SD, Sharp PA, Charest A, Bhatia S. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009 Sep 22; 3(9): 2495‐504.
  18. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008 Dec; 76(10): 1081‐92.
  19. Xing D, Orsulic S. A mouse model for the molecular characterization of Brca1‐associated ovarian carcinoma. Cancer Res. 2006 Sept 15; 66(18): 8949‐53.
  20. Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway‐targeted therapy and tumor resistance. Proc Natl Acad Sci USA. 2005 102: 6936‐41.
  21. Wang YG, Xing D, Tan W, Wang LJ, Tang PZ, Lin DX. Poly(AT) polymorphism in DNA repair gene XPC and lung cancer risk. Zhonghua Zhong Liu Za Zhi. 2003 Nov;25(6):555‐7. Chinese.
  22. Tan W, Qi J, Xing D, Miao XP, Pan KF, Zhang L, Lin DX. Relation between single nucleotide polymorphism in estrogen‐metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):453‐6. Chinese.
  23. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, Lin D. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer. 2003 Jul 10; 105(5): 669‐73.
  24. Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O6‐ methylguanine‐ DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis. 2003 Jun; 24(6): 1039‐44.
  25. Yu C, Lu W, Tan W, Xing D, Liang G, Miao X, Lin D. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2): 176.
  26. Xing D, Qi J, Tan W, Miao XP, Liang G, Yu CY, Lu WF, Zhou CN, Wu M, Lin DX. Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Feb;20(1):35‐8. Chinese.
  27. Lu W, Qi J, Xing D, Tan W, Miao X, Su W, Wu M, Lin D. Lung cancer risk associated with genetic polymorphism in myeloperoxidase (‐463 G/A) in a Chinese population. Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):250‐3. Chinese.
  28. Qi J, Tan W, Xing D, Miao X, Lin D. Study on the association between smoking behavior and dopamine receptor D2 gene polymorphisms among lung cancer cases. Zhonghua Liu Xing Bing Xue  Za Zhi. 2002 Oct;23(5):370‐3. Chinese.
  29. Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase‐2 promoter and risk of lung cancer. Cancer Res. 2002 Nov 15; 62(22): 6430‐3.
  30. Miao X, Xing D, Tan W, Qi J, Lu W, Lin D. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at‐risk Chinese population. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11(11): 1454‐8.
  31. Xing D, Tan W, Wei Q, Lin D. Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer. 2002 Nov; 38(2): 123‐9.
  32. Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not GSTM1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002 Nov 20; 102(3): 275‐9.
  33. Miao X, Xing D, Tan W, Lu W, Lin D. Single nucleotide polymorphisms in methylenetetrahydrofolate reductase gene and susceptibility to cancer of the gastric cardia in Chinese population. Zhonghua Yi Xue Za Zhi. 2002 May 25;82(10):669‐72. Chinese.
  34. Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer. 2002 Aug 10; 100(5): 600‐5.
  35. Zhang L, Xing D, He Z, Lin D. p53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Feb;19(1):10‐3. Chinese.
  36. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 2001 Apr; 61(8): 3272‐5.
  37. Xing D, Tan W, Song N, Lin DX. Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer. 2001 May 20; 95(3): 140‐3.
  38. Tan W, Chen GF, Xing D, Song CY, Kadlubar FF, Lin DX. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer. 2001 Mar 20; 95(2): 96‐101.
  39. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case‐control study in China. Carcinogenesis. 2001 Jan; 22(1): 11‐6.
  40. Xing D, Tan W, Song N, Lin D. Genetic polymorphism in hOGG1 and susceptibility to esophageal cancer in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2000 Dec; 17 (6):377‐80. Chinese.
Review Articles
  1. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population. (Review). Oncol Rep. 2003 Sep‐Oct; 10(5): 1615‐23.
  2. Xing D, Orsulic S. Modeling resistance to pathway‐targeted therapy in ovarian cancer. Cell Cycle. 2005 4(8): 1004‐6.
Case Reports
  1. Xing D, Berrebi AA, Liu C, Richmond A, Vang R, Ronnett BM. An Epithelioid Smooth Muscle Neoplasm Mimicking a Signet Ring Cell Carcinoma in the Ovary. Int J Gynecol Pathol. Accepted and in press.
  2. Zheng G, Richmond A, Liu C, Berrebi A, Pallavajjala A, Haley L, Stone RL, McCarthy E, Vang R, Xing D. Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus. Int J Gynecol Pathol. 2018 Apr 6. [Epub ahead of print].
  3. Xing D, Jenson EG, Zwick CA, M.D, Rodriguez FJ, Kurman RJ. Atypical Proliferative (Borderline) Serous Tumor in the Brain: A Case Report. Int J Gynecol Pathol. 2018 Jan;37(1):52‐56.

Pathology and Therapeutics Flyer